NCT05402839 Screening of Malignant Hyperthermia Susceptible Individuals
| NCT ID | NCT05402839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Malignant Hyperthermia |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-02-22 |
| Primary Completion | 2041-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-02-22 with a primary completion date of 2041-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study intends to target patients who underwent surgery under general anesthesia during the study period and developed malignant hyperthermia during or after surgery. Therefore, the total sample size was estimated to be about 50 people based on the past incidence of this rare disease. Every year, about 20 patients and their families who developed malignant hyperthermia during or after surgery will participate in this nationwide study (estimated by the current incidence of malignant hyperthermia), and about 1-5 patients will be admitted to Peking University Third Hospital participate in this research. Relevant specimens were collected from malignant hyperthermia (MH) patients and their family members for genetic analysis to determine the mutation of MH-related pathogenic gene loci.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing surgery under general anesthesia during the study period developed malignant hyperthermia during or after surgery. Exclusion Criteria: * Malignant hyperthermia was ruled out by later treatment and diagnosis; * The patient or family member refuses to be recruited.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05402839 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 100 Years, studying Malignant Hyperthermia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05402839 currently recruiting?
Yes, NCT05402839 is actively recruiting participants. Contact the research team at quyinyin@bjmu.edu.cn for enrollment information.
Where is the NCT05402839 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05402839 clinical trial?
NCT05402839 is sponsored by Peking University Third Hospital. The trial plans to enroll 50 participants.